SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 25, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




           Delaware                                    52-1555759
        (State of Incorporation)                     (I.R.S. Employer
           Identification No.)



              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)


      Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 21, 1999:

http://www.medimmune.com

FOR IMMEDIATE RELEASE

Contacts:
Mark E. Kaufmann                 William C. Roberts
Director, Planning and Analysis  Investor and Media Relations
MedImmune, Inc.                  MedImmune, Inc.
301-417-0770 x321                301-417-0770 x358
http://www.medimmune.com


MedImmune to Redeem $60 Million of 7 Percent Convertible Subordinated Notes
Due 2003

Gaithersburg, MD, May 21, 1999 -- MedImmune, Inc. (Nasdaq: MEDI) today announced
that  it  will  call  for  redemption  its  outstanding  7  percent  Convertible
Subordinated  Notes due 2003. The Notes are  convertible  into MedImmune  common
stock at $9.84 per share (equivalent to 101.626 shares for each $1,000 principal
amount).  Unless  previously  converted,  all  outstanding  Notes,  with a total
principal amount of $60 million, will be redeemed on July 7, 1999.

Norwest  Bank  Minnesota,  N.A.  will send to  registered  holders  of the Notes
Letters of  Transmittal  by which  holders  can elect to convert  their Notes or
submit them for  redemption.  Holders have until July 6, 1999 to submit Notes to
Norwest for conversion. Holders submitting Notes for conversion prior to July 1,
1999 will not be entitled to the July 1 interest payment. Those converting after
July 1 will receive the July 1 interest  payment but are not entitled to further
interest  payments.  Holders who do not convert by July 6, 1999 will receive the
redemption price of $1,041.36 per $1,000 principal amount.

Conversion or redemption of the Notes will result in interest expense savings to
MedImmune of approximately $16.8 million over the remaining life of the

Notes.  Assuming full conversion,  the Company's long-term debt would be reduced
and shareholders'  equity would increase by approximately  $60 million.  Diluted
shares outstanding at March 31, 1999 of 65.5 million already reflect shares into
which the Notes are convertible.

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.
                                    ####




(REGISTRANT)      MEDIMMUNE, INC.



BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 25, 1999
[{"type": "8-K", "sequence": "1", "description": "MEDIMMUNE TO REDEEM $60 MILLION OF 7 PERCENT", "secsgml_size_bytes": 4225}]
{"company-data": {"conformed-name": "MEDIMMUNE INC /DE", "cik": "0000873591", "assigned-sic": "2836", "irs-number": "521555759", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14657", "film-number": "99633832"}, "business-address": {"street1": "35 W WATKINS MILL RD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878", "phone": "3014170770"}, "mail-address": {"street1": "35 W WATKINS MILL ROAD", "city": "GAITHERSBURG", "state": "MD", "zip": "20878"}}
SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 25, 1999

                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)

                         Commission File Number: 0-19131

           Delaware                                    52-1555759
        (State of Incorporation)                     (I.R.S. Employer
           Identification No.)

              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)

      Registrant's telephone number, including area code (301) 417-0770

                No Exhibits are being filed with this report

CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K

ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 21, 1999:

http://www.medimmune.com

FOR IMMEDIATE RELEASE

Contacts:
Mark E. Kaufmann                 William C. Roberts
Director, Planning and Analysis  Investor and Media Relations
MedImmune, Inc.                  MedImmune, Inc.
301-417-0770 x321                301-417-0770 x358
http://www.medimmune.com

MedImmune to Redeem $60 Million of 7 Percent Convertible Subordinated Notes
Due 2003

Gaithersburg, MD, May 21, 1999 -- MedImmune, Inc. (Nasdaq: MEDI) today announced
that  it  will  call  for  redemption  its  outstanding  7  percent  Convertible
Subordinated  Notes due 2003. The Notes are  convertible  into MedImmune  common
stock at $9.84 per share (equivalent to 101.626 shares for each $1,000 principal
amount).  Unless  previously  converted,  all  outstanding  Notes,  with a total
principal amount of $60 million, will be redeemed on July 7, 1999.

Norwest  Bank  Minnesota,  N.A.  will send to  registered  holders  of the Notes
Letters of  Transmittal  by which  holders  can elect to convert  their Notes or
submit them for  redemption.  Holders have until July 6, 1999 to submit Notes to
Norwest for conversion. Holders submitting Notes for conversion prior to July 1,
1999 will not be entitled to the July 1 interest payment. Those converting after
July 1 will receive the July 1 interest  payment but are not entitled to further
interest  payments.  Holders who do not convert by July 6, 1999 will receive the
redemption price of $1,041.36 per $1,000 principal amount.

Conversion or redemption of the Notes will result in interest expense savings to
MedImmune of approximately $16.8 million over the remaining life of the

Notes.  Assuming full conversion,  the Company's long-term debt would be reduced
and shareholders'  equity would increase by approximately  $60 million.  Diluted
shares outstanding at March 31, 1999 of 65.5 million already reflect shares into
which the Notes are convertible.

MedImmune, located in Gaithersburg, Maryland, is a biotechnology company focused
on developing and marketing products that address medical needs in areas such as
infectious disease,  transplantation medicine,  autoimmune disorders and cancer.
MedImmune markets three products through its hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S. Securities and Exchange Commission.
                                    ####

(REGISTRANT)      MEDIMMUNE, INC.

BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 25, 1999